|
Fourth quarter (1 October – 31 December 2018)
· Net sales for the quarter amounted to TSEK 0 (0).
· Operating profit (EBIT) was TSEK -3 249 (-2 599).
· Operating cash flow was TSEK -3 806 (-2 632).
· Profit after tax amounted to TSEK -3 242 (-2 599).
· Corresponding to SEK -0,04 (-0,04) per share.
Full-year (1 January – 31 December 2018)
· Net sales for the period amounted to MSEK 0 (0).
· Operating profit (EBIT) was TSEK -11 821 (-8 535).
· Operating cash flow was TSEK -10 864 (-9 095).
· Profit after tax amounted to TSEK -11 814 (-8 535).
· Corresponding to SEK -0,16 (-0,14) per share.
For further information, please contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90
Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46(0)
8 503 000 50
This information is information that SpectraCure AB is required to disclose
under the EU Market Abuse Regulation. The information was provided, through the
contact of the above contact person, for publication on February 15th, 2019.
SpectraCure in short
SpectraCure was founded in 2003 as a spin off from Lund University departments
for medical laser applications and physics. The company focuses on cancer
treatments using medical systems with laser light sources and reactive drugs,
which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment
methodology suitable for internal solid tumours of various kind, e.g. prostate
and abdominal salivary glands, but also other indications such as cancer tumours
in the head and neck region |